Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
holding | CYCN | Common Stock | 21.7K | Nov 30, 2023 | Direct | F1 |
Id | Content |
---|---|
F1 | Prior to becoming a Reporting Person, Mr. Higgins held 1,650 shares of common stock of Cyclerion Therapeutics, Inc. On November 30, 2023, the Reporting Person was granted 20,000 shares of restricted stock pursuant to the Cyclerion Therapeutics, Inc. 2019 Equity Incentive Plan, of which 2,500 of these shares vest immediately and the remaining 17,500 shares vest ratably over a 42-month period, provided that the Reporting Person remains as a director of Cyclerion Therapeutics, Inc. on such applicable vesting date, subject to certain exemptions. |